Promising Activity Seen With Nivolumab in Refractory Classical Hodgkin Lymphoma

December 6, 2014 6:45 PM

3 0

Most patients with classical Hodgkin lymphoma (cHL), having previously failed three or more therapies, responded to the immunotherapy nivolumab in a small phase I trial.

The PD-1 inhibitor has been granted breakthrough therapy designation by the FDA as a result, and is now being investigated in a large phase II trial, according to the authors of the study. Lead author Philippe Armand, MD, PhD, of the Dana-Farber Cancer Institute in Boston, presented the findings Dec...

Read more

To category page

Loading...